Skip to main content

Seres Therapeutics, Inc.

MCRB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001609809

In the last 90 days, Seres Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 35 institutions reported holding it in 13F filings for Q2 2026, worth $17.9M in total; no superinvestor holds it.

Q4 2024 vs. Q3 2024

How the institutions holding Seres Therapeutics, Inc. changed between Q3 2024 and Q4 2024.

All holders in Q4 2024All holders in Q3 2024

13F holders of MCRB: Q3 2024 compared with Q4 2024
MeasureQ3 2024Q4 2024Change
Holders7769−8
Shares63.5M63.1M−420.0K (−0.7%)
Value$60.1M$52.5M−$7.59M (−12.6%)

New holders (9)

Institutions that held Seres Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.

Institutions new to MCRB in Q4 2024
InstitutionSharesValue% of portfolio
HRT Financial LP26,868$22.0K0.00%
Two Sigma Investments, LP24,412$20.3K0.00%
SBI Securities Co., Ltd.21,651$18.0K0.00%
XTX Topco Ltd16,300$13.5K0.00%
Integrated Wealth Concepts LLC10,000$8.31K0.00%
Tower Research Capital LLC (TRC)9,325$7.75K0.00%
Bell Investment Advisors, Inc611$5080.00%
Jones Financial Companies LLLP49$410.00%
Citadel Advisors LLC31$260.00%

Sold out (17)

Institutions that held Seres Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.